Allstate (NYSE:ALL) Price Target Raised to $207.00 at JPMorgan Chase & Co.

Allstate (NYSE:ALLGet Free Report) had its price target upped by equities research analysts at JPMorgan Chase & Co. from $205.00 to $207.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 9.97% from the stock’s current price.

ALL has been the subject of a number of other reports. TD Cowen boosted their price target on Allstate from $193.00 to $224.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Wells Fargo & Company decreased their price target on Allstate from $177.00 to $175.00 and set an “equal weight” rating for the company in a report on Friday, August 16th. Roth Mkm reaffirmed a “buy” rating and set a $200.00 target price on shares of Allstate in a research note on Wednesday, August 14th. Piper Sandler upped their target price on Allstate from $188.00 to $196.00 and gave the stock an “overweight” rating in a research note on Friday, August 16th. Finally, BMO Capital Markets upped their target price on Allstate from $191.00 to $205.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $199.24.

Get Our Latest Stock Analysis on Allstate

Allstate Trading Up 1.3 %

Shares of NYSE:ALL opened at $188.24 on Thursday. Allstate has a 12-month low of $113.04 and a 12-month high of $193.97. The company has a market capitalization of $49.70 billion, a PE ratio of 17.19, a PEG ratio of 1.74 and a beta of 0.48. The business has a 50 day moving average of $184.04 and a two-hundred day moving average of $172.89. The company has a current ratio of 0.36, a quick ratio of 0.36 and a debt-to-equity ratio of 0.49.

Allstate (NYSE:ALLGet Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $1.28. Allstate had a return on equity of 24.05% and a net margin of 5.03%. The company had revenue of $15.71 billion during the quarter, compared to the consensus estimate of $14.04 billion. During the same period in the previous year, the company posted ($4.42) earnings per share. Allstate’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, analysts forecast that Allstate will post 15.19 EPS for the current year.

Insider Buying and Selling at Allstate

In other Allstate news, insider Suren Gupta sold 45,775 shares of the company’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $177.28, for a total value of $8,114,992.00. Following the completion of the sale, the insider now directly owns 89,930 shares in the company, valued at $15,942,790.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Allstate news, EVP Elizabeth Brady sold 49,481 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $179.09, for a total value of $8,861,552.29. Following the completion of the sale, the executive vice president now directly owns 19,163 shares in the company, valued at $3,431,901.67. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suren Gupta sold 45,775 shares of the stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $177.28, for a total value of $8,114,992.00. Following the transaction, the insider now owns 89,930 shares of the company’s stock, valued at approximately $15,942,790.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 238,305 shares of company stock worth $43,082,657 in the last three months. 1.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Allstate

Hedge funds have recently modified their holdings of the business. Rise Advisors LLC purchased a new position in shares of Allstate during the 1st quarter worth $26,000. Northwest Investment Counselors LLC purchased a new position in shares of Allstate during the 1st quarter worth $26,000. Versant Capital Management Inc grew its holdings in shares of Allstate by 70.9% during the 2nd quarter. Versant Capital Management Inc now owns 188 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 78 shares during the period. Family Firm Inc. purchased a new position in shares of Allstate during the 2nd quarter worth $38,000. Finally, MCF Advisors LLC grew its holdings in shares of Allstate by 33.9% during the 2nd quarter. MCF Advisors LLC now owns 332 shares of the insurance provider’s stock worth $53,000 after purchasing an additional 84 shares during the period. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

Allstate Company Profile

(Get Free Report)

The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. It operates in five segments: Allstate Protection; Protection Services; Allstate Health and Benefits; Run-off Property-Liability; and Corporate and Other segments.

Read More

Analyst Recommendations for Allstate (NYSE:ALL)

Receive News & Ratings for Allstate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allstate and related companies with MarketBeat.com's FREE daily email newsletter.